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ABSTRACT
Introduction: To assess the impact of cer-
tolizumab pegol (CZP) treatment on clinical,
patient-reported, and musculoskeletal ultra-
sound outcomes and to determine the treat-
ment response time point most predictive of
long-term outcomes in Italian patients with
rheumatoid arthritis (RA).
Methods: CZP-SPEED (NCT01443364) was a
52-week, open-label, prospective, interven-
tional, multicenter study. Biologic-naı¨ve
patients with moderate-to-severe active RA,
who had failed at least one DMARD treatment,
received CZP (400 mg at weeks 0, 2, and 4, then
200 mg every 2 weeks) concomitantly with
methotrexate. The primary objective was to
identify the time point of clinical response
{decrease in 28-joint Disease Activity Score
[DAS28(ESR)] C 1.2} most predictive of a clini-
cal response at week 52. Additional clinical and
patient-reported outcomes were measured.
Power Doppler (PD) ultrasound was used to
assess synovial effusion, synovial proliferation,
PD signal, cartilage damage, and bone erosion
according to international guidelines.
Results: A total of 132 patients were enrolled
and received CZP; 91/132 (69%) completed to
week 52. Predicted 52-week responses for early
responders (week 2 onwards) were between 65%
and 70%. Rapid improvements in joint cavity
widening and PD signal were observed to week 8
and maintained to week 52. Cartilage damage
and bone erosion were stable over 52 weeks. No
new safety signals were identified.
Conclusion: In Italian CZP-treated patients
with moderate-to-severe RA, week 12 clinical
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responses may be predictive of long-term
response at week 52. Rapid improvements in
clinical, patient-reported, and musculoskeletal
ultrasound outcomes were maintained to week
52. These data may aid rheumatologists to make
earlier treatment decisions.
Trial Registration: ClinicalTrials.gov identifier,
NCT01443364.
Funding: UCB Pharma.
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INTRODUCTION
Tumor necrosis factor alpha inhibitors (anti-
TNFs) are an established treatment option for
rheumatoid arthritis (RA), capable of amelio-
rating disease activity, slowing progression of
joint damage, and improving health-related
quality of life [1].
Certolizumab pegol (CZP) is a PEGylated, Fc-
free anti-TNF that, owing to its innovative
structure, exerts a prolonged half-life [2] and
potentially different pharmacokinetic proper-
ties compared to other anti-TNF agents [3];
evidence from murine models suggests that CZP
may be able to penetrate inflamed arthritic tis-
sue to a greater extent compared to infliximab
and adalimumab [3–6].
Previous research from the RAPID-1 trial
indicates that patients who do not achieve a
28-joint Disease Activity Score [DAS28(ESR)]
response within the first 12 weeks of CZP and
methotrexate (MTX) combination therapy are
unlikely to reach low disease activity (LDA) at
12 or 52 weeks [7, 8]. However, since these
observations were based on post hoc analyses,
further studies are required to support these
predictability results. This early identification of
patients who do not respond to CZP therapy
can help physicians follow treat-to-target rec-
ommendations [9], facilitating earlier reassess-
ment of current treatment. This is likely to lead
to more rapid achievement of clinical goals.
Power Doppler ultrasound (PDUS) is a
straightforward, noninvasive imaging instrument
employed to evaluate both clinical and subclini-
cal synovitis [10–15], which can be used alongside
clinical and patient-reported outcomes (PROs) in
order to assess disease activity. Prior research on
the usage of PDUS in rheumatology has proven its
reliability and sensitivity. This tool is able to
visualize the synovial inflammatory joint changes
in RA that may have previously gone undetected
by conventional clinical and radiographic exam-
inations [10]. Furthermore, previous studies sug-
gest that PDUS brings additional value alongside
clinical examination, both in improving early
diagnosis of RA through the detection of sub-
clinical synovitis as well as establishing whether
true RA remission has been achieved [16–18].
Thus PDUS can be used to support the diagnosis
process and may help to predict long-term clini-
cal outcomes—an indispensable advantage for
clinicians. According to the Italian Society of
Rheumatology (SIR) recommendations for the use
of biologics in RA, synovitis assessed by PDUS
may be considered as an image biomarker for
poor prognostic features [17, 19].
The primary objective of this study was to
identify the time point of clinical response with
the highest predictive value at week 52. The
secondary study objective was to assess the
PDUS response over time in a subgroup of
patients. In order to achieve these objectives,
CZP efficacy, safety, and predictability in terms
of clinical, PROs, and PDUS outcomes were
assessed over 52 weeks in a cohort of Italian
patients with moderate-to-severe RA. We
hypothesized that CZP treatment would
improve clinical outcomes, PROs, and PDUS
outcomes after 52 weeks.
METHODS
Study Design
The CZP-SPEED study (NCT01443364 and
EudraCT 2011-000385-35) was a 52-week, open-
label, prospective, interventional, multicenter
study which evaluated the predictability of dis-
ease control atweek52basedon early response to
CZP (in combination with MTX) in Italian
patients with RA. CZP was supplied by UCB
Pharma. Concomitant use of oral corticosteroids
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(B 10 mg/day prednisone, or equivalent) and
non-steroidal anti-inflammatory drugs (NSAIDs)
was permitted at stable doses during the course of
the study. Analgesics without anti-inflammatory
action and oral opioid analgesics were also per-
mitted during the study but could not be used
prior to clinical assessments on the day of a
scheduled visit. Assessments were carried out at
weeks 0, 1, 2, 4, 6, 8, 12, 24, 36, and 52.
Patients
Patients enrolled in the trial were biologic-
naı¨ve, had moderate-to-severe RA (defined as at
least six swollen and at least six tender joints)
and had failed treatment with at least one dis-
ease-modifying anti-rheumatic drug (DMARD);
which is in line with the indication of CZP
stated in the approved label [Summary of pro-
duct Characteristics (SmPC)] [20]. Patients were
treated with CZP (400 mg at weeks 0, 2 and 4,
followed by 200 mg every 2 weeks) in combi-
nation with MTX (C 15 or B 25 mg per week,
unless limited by subject intolerance or toxic-
ity). The doses of CZP used in the study were in
agreement with the approved label (SmPC) for
treatment of RA with CZP [20]. The safety set
(SS) consisted of all patients who received at
least one dose of CZP. The full analysis set (FAS)
consisted of all patients in the SS who had a
valid baseline and post-baseline efficacy mea-
surement for the primary objective. A subgroup
of these patients (the PDUS subgroup) provided
additional ultrasound and radiographic imag-
ing evaluations if they had been diagnosed with
RA for at most 2 years and they presented with
at least two of the following PDUS findings:
synovial proliferation, synovial vascularization,
or presence of fluid in at least one metacar-
pophalangeal (MCP) joint.
Compliance with Ethics Guidelines
All procedures performed in studies involving
human participants were in accordance with
the ethical standards of the responsible Italian
authorities [the Agenzia Italiana del Farmaco
(AIFA)] and with the 1964 Helsinki declaration
and its later amendments or comparable ethical
standards. Informed consent was obtained from
all participants included in the study.
Study Procedures and Evaluations
The primary objective was to detect the time
point of clinical response with the highest posi-
tive predictive value (PPV). PPV was defined as
the percentage of patients with a clinical
response [reduction frombaseline inDAS28(ESR)
of at least 1.2] up to week 12, who also had clin-
ical response [reduction from baseline in
DAS28(ESR) of at least 1.2] at week 52.
Additional clinical exploratory variables inclu-
ded American College of Rheumatology ACR20/
50/70 response [21], DAS28(ESR), DAS28(CRP),
Patient Global Assessment of Disease Activity
(PtGADA) [22], Physician Global Assessment of
Disease Activity (PhGADA), Patient Assessment of
Arthritis Pain (PtAAP), and Health Assessment
Questionnaire Disability Index (HAQ-DI) [21].
Imaging Evaluations
The secondary objective of the study was to
observe the effectiveness of PDUS in assessing
both disease activity and impact of treatment in
the subgroup of subjects undergoing PDUS.
Additionally, the degrees of joint damage of the
hands, wrists, and feet were assessed radio-
graphically using the van der Heijde modified
total Sharp score (mTSS) in the PDUS subgroup
of patients [23, 24].
The second and third MCP joints, bilaterally
together with another MCP joint (the most
clinically involved), were examined by ultra-
sound measurements at weeks 0, 1, 2, 4, 6, 8, 12,
24, 36, and 52. Ultrasound variables under
evaluation were joint cavity widening, synovial
proliferation, Power Doppler (PD) signal (syn-
ovial vascularization), bone erosion, and carti-
lage damage score measurements according to
international guidelines. Joint cavity widening
and PD signal were scored from 0 to 3 depend-
ing on the extent of synovial effusion and/or
proliferation [25, 26] and the level of PD signal
at the synovial tissue [27, 28], respectively.
Cartilage damage and bone erosions were
scored from 0 to 4 on the basis of metacarpal
cartilage thickness at the MCP joint level
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[29, 30] and diameter of bone erosion per joint
[26, 31], respectively. PDUS sum scores were the
sum of the scores generated using these two
semiquantitative scoring systems [25, 27].
A standardized instrumentation (MyLab
TM70 XVG or Mylab TMTwice-Esaote Biomedica,
or GE Logiq 9, equipped with a broadband lin-
ear probe of 6–18 MHz) and operational tech-
nique was adopted with multiplanar scanning
technique on dorsal, lateral, and volar aspects of
the MCP joints. All sonographers were trained
before the start of the study. All images were re-
assessed by an assigned ultrasound expert reader
and analyzed for inter-reader reliability.
Safety Measurements
Safety measurements assessed included adverse
events (AEs) classified by system organ class
(SOC) and preferred term (PT) using the Medical
Dictionary for Regulatory Activities (MedDRA)
version 18.0. Only treatment-emergent AEs
(TEAEs) were included in the summary tables.
Statistical Analysis
The SS consisted of all enrolled patients who
received at least one dose of study medication.
Clinical outcomes and PROs were assessed in
the full analysis set (FAS), defined as all patients
who received at least one dose of CZP and had
at least one baseline and at least one post-
baseline DAS28(ESR) assessment (the primary
clinical variable). PDUS outcomes were assessed
in a subgroup of enrolled patients with RA dis-
ease duration less than 2 years and proof of at
least two of the following: synovial prolifera-
tion, synovial vascularization, and presence of
fluid in at least one selected joint.
A sample size of 120 patients was calculated to
be appropriate to produce 95% confidence inter-
vals (CIs) with sufficient precision (± 0.069) to
estimate predictability for the base case of a 60%
response rate. Precision would be higher if the
proportion of responders was greater than 60%. At
least 40 (33.3%) of the 120 included patients were
planned to be part of the PDUS subgroup of
patients.
In order to analyze the primary objective,
DAS28(ESR) was measured at weeks 1, 2, 4, 6, 8,
and 12 and was used to predict maintenance of
long-term efficacy in CZP-treated patients, using
the PPV and negative predictive values (NPV).
Logistic regression was performed post hoc to
evaluate the predictive ability of early respon-
ders, up to week 12, and long-term efficacy at
week 52, after controlling for the prognostic
factors [baseline DAS28(ESR), gender, age, and
duration of RA]. Area under curve (AUC) was
obtained from fitting the logistic regression
model with week 52 response as the dependent
variable and early response (weeks 1–12) as the
independent variable. The model with the max-
imum AUC was considered the better predictor.
PPV was defined using the equation: [32] nN 
100; where n is the number of patients with a
clinical response at week 52 and a clinical
response at a specified early time point, and N is
all patients with a clinical response at a specified
early time point. Clinical response was defined
as a reduction in DAS28(ESR) of at least 1.2. For
NPV, n is the number of patients who did not
have a clinical response at week 52 nor a clinical
response at a specified early time point.
A mixed effects linear model for repeated
measures was used to examine the effect of each
of the prognostic factors on the sum scores
describing disease activity (joint cavity widen-
ing, synovial proliferation, and PD signal/blood
flow) and disease severity (progression in carti-
lage damage and bone erosions). Within this
model, ‘‘week’’ was a repeated measure and the
prognostic factors [baseline DAS28(ESR), gen-
der, age, duration of RA] were fixed effects. The
regression coefficient, standard error (SE), and
p values associated with each prognostic factor
are presented. During a post hoc analysis,
patient duration of RA and the presence or
absence of bone erosion were assessed for PDUS
outcomes. Correlation analysis was conducted
between PDUS and mTSS at each visit using the
Spearman’s correlation coefficient. Inter-reader
reliability of all six joints was assessed in a
subgroup of the PDUS patients at baseline and
weeks 6, 12, and 36 using a blinded expert to
review the images for PD signal/blood flow and
cartilage damage. The first and second readings
of the images were analyzed for inter-reader
reliability using Cohen’s kappa statistics.
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Missing data were imputed using non-re-
sponder imputation (NRI) for categorical data
and last observation carried forward (LOCF) for
continuous data.
RESULTS
Patient Disposition and Baseline
Characteristics
In total, 132 patients were enrolled and received
CZP (SS) between December 2011 and May
2015, of whom 131 (99%) comprised the FAS,
and 91 (69%) completed to week 52 (Fig. 1). The
primary reasons for discontinuation included
adverse events (15 patients), lack of efficacy (14
patients), loss to follow-up (3 patients), consent
withdrawn (5 patients), and other (4 patients)
(Fig. 1). The PDUS subgroup consisted of 66
(50.0%) patients, and 43/66 (65.2%) PDUS
patients completed to week 52 (Fig. 1). The
primary reasons for discontinuation in the
PDUS subgroup included adverse events (9
patients), lack of efficacy (8 patients), loss to
follow-up (2 patients), consent withdrawn (3
patients), and other (1 patient) (Fig. 1).
Fig. 1 CONSORT diagram showing patient disposition
throughout the SPEED study. aPatients who provided
DAS28(ESR) values (observed case). bPatients who pro-
vided joint cavity widening and synovial proliferation
values (observed case). FAS full analysis set, PDUS Power
Doppler ultrasound, SS safety set
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Baseline characteristics were similar between
the FAS and PDUS subgroup (Table 1). Charac-
teristics by duration of RA prior to study enroll-
ment are shown in Supplementary Table S1. At
baseline, 131/132 (99.2%) enrolled patients had
previously taken, or were taking, concomitant
DMARDs, including methotrexate [126 (95.5%)
patients], methotrexate sodium [6 (4.5%)
patients], and leflunomide [3 (2.3%) patients].
Prior and concomitant use of permitted
medications (corticosteroids, NSAIDs, non-anti-
inflammatory analgesics, and oral opioid anal-
gesics) are reported in Supplementary Table S2.
Predictability
DAS28(ESR) response [DAS28(ESR) C 1.2 from
baseline] rates were 70% by week 4 of treatment
and remained at a similar level for the
Table 1 Patient characteristics at baseline for the full analysis set and PDUS subgroup
Mean (SD), unless otherwise stated Full analysis set n = 131 PDUS subgroupa n = 66
Age, years 54.8 (13.2) 53.4 (13.7)
Female, n (%) 107 (81.7) 54 (81.8)
Disease duration, median (min; max) 1.8 (0; 5) 1.5 (1; 2)
B 2 years, n (%) 88 (67.2) 66 (100.0)
[ 2 years, n (%) 43 (32.8) 0 (0.0)
With extra-articular features, n (%) 16 (12.2) 7 (10.6)
Duration of morning stiffness, median hours (min; max) 1.0 (0; 24) 1.0 (1; 24)
\ 2 h, n (%) 92 (70.2) 51 (77.3)
C 2 h, n (%) 39 (29.8) 15 (22.7)
DAS28(ESR) 5.9 (1.1) 5.7 (1.0)
DAS28(CRP) 5.3 (1.0) 5.1 (1.0)
HAQ-DI 1.3 (0.7) 1.3 (0.7)
PtAAP 56.5 (23.4) 53.8 (24.3)
PtGADA 57.3 (23.2) 53.5 (24.1)
PhGADA 56.6 (19.1) 52.0 (18.9)
PDUS sum score – 20.5 (11.7)
mTSS, median (min; max) 20.0 (0; 121) 20.0 (0; 121)
ESR, median mm/h (min; max) 35.0 (2; 140) 32.0 (2; 105)
CRP median mg/L (min; max) 6.4 (0; 201) 5.3 (0; 201)
Bone erosion,b n (%) 45 (34.4) 43 (65.2)
CRP C-reactive protein, DAS28 28-joint disease activity score, ESR erythrocyte sedimentation rate, FAS full analysis set,
HAQ-DI health assessment questionnaire-disability index, mTSS modiﬁed total Sharp score, PDUS Power Doppler
ultrasound score, PtAAP patient’s assessment of arthritis pain, PtGADA patient’s global assessment of disease activity,
PhGADA physician’s global assessment of disease activity, VAS visual analogue scale
a PDUS subgroup deﬁned as patients with duration of RA\ 2 years
b Bone erosion measured by ultrasound and reported as number of erosions
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remainder of the trial (Supplementary Fig. S1).
Patients with disease duration of at most 1 year
were less likely to experience DAS28(ESR)
response compared to patients with more
established disease (Supplementary Fig. S2b). Of
the patients who responded with a DAS28(ESR)
reduction of at least 1.2 at an early time point
(week 2–12), this clinical response was still
observed for 65–70% at week 52 (Fig. 2).
The week with the numerically greatest PPV
was week 8, with 69.8% responders reporting at
least a 1.2 point reduction in DAS28(ESR) at
week 52; however, the predictive values of all
time points from week 2 onwards were compa-
rable (Fig. 2). Patients with disease duration of
over 1 year had higher PPV and lower NPV
outcomes compared to patients with shorter
disease duration at all time points (Fig. 3). The
post hoc logistic regression analysis did not
identify any significant prognostic factors for
predictability (Fig. 4).
Clinical and Radiographic Outcomes
Rapid improvements in clinical and patient-re-
ported outcomes were observed from week 1 to
week 12 and were maintained to week 52
(Fig. 5), including an improvement in
DAS28(ESR) of - 2.31 from baseline to week 52
(Fig. 5a). However, no significant correlation
between PDUS outcomes and DAS28(ESR) was
observed.
The proportion of patients achieving ACR20/
50/70 increased to week 12 (67.2%/41.2%/
23.7%) and was maintained to week 52 (61.8%/
47.3%/29.8%) (Fig. 5b). Mean improvement in
HAQ-DI of - 0.57 from baseline to week 52
(Fig. 5c) and in PtAAP (- 26.2 change from
baseline to week 52; Fig. 5d) was observed.
Within the PDUS subgroup, mTSS scores
remained approximately constant over the
course of the study [median (standard devia-
tion; SD) 20.0 (32.0) at baseline, median change
from baseline 1.0 (15.8) at week 52] suggesting
inhibition of radiographic progression in these
patients (Supplementary Fig. S5).
PDUS Outcomes
Rapid reductions in joint cavity widening were
observed to week 8 across joints analyzed,
which were maintained to week 52 (Fig. 6a).
Patients with presence of bone erosion had
higher levels of joint cavity widening at baseline
and experienced the greatest levels of joint
cavity widening reduction over time (Supple-
mentary Figs. S3a, b). There was also a rapid
decrease in the PD signal at a joint level by week
8, which was maintained through week 52
(Fig. 6b). Patients with measurable bone erosion
at baseline had higher PD signals overall, but
also reported a greater level of improvement
following CZP treatment (Supplementary
Figs. S3c, d). Cartilage damage and bone erosion
were stable over 52 weeks (Supplementary
Fig. S4), indicating a lack of progression during
the treatment period. Similarly, radiographic
analysis of joints by mTSS showed that joint
damage remained stable over 52 weeks (Sup-
plementary Fig. S5). Correlation analysis at
weeks 4, 12, and 52 between PDUS and mTSS
resulted in correlation coefficients of at least
0.526 and p\0.001. Inter-reader reliability of
the readings of PDUS images (representative
PDUS images provided in Supplementary
Fig. 2 Positive predictive value (PPV): percentage of
patients with DAS28(ESR) clinical response at week 52
who also had clinical response at an early time point. Data
reported for the full analysis set, n = 131. Missing values
were imputed using non-responder imputation (NRI).
Clinical response was deﬁned as a reduction of at least 1.2
in DAS28(ESR). DAS28 28-joint disease activity score,
ESR erythrocyte sedimentation rate, NRI non-responder
imputation, PPV positive predictive value
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Fig. S6) ranged from good (kappa[0.75) at
week 0 to moderate (kappa 0.4–0.75) at later
time points in the study.
The mixed effect with repeated measures
analysis indicated that duration of RA (\ 1 year
vs. C 1–\ 2 years) had a significant effect on the
sum of the joint cavity widening, synovial pro-
liferation, and PD signal (Table 2). Similar
results were reported for the sum of the pro-
gression of cartilage damage and bone erosion
scores (Table 2). Study site was not included as a
fixed effect in these analyses as patient enroll-
ment by study center was low (at most 11
patients). Two study sites had higher patient
enrollment (24 and 27 patients) and the inclu-
sion of site as a fixed variable (sites with high
enrollment vs others) showed that the former
did not have a significant effect on clinical
response at week 52 (p[0.05 for both sites). A
post hoc analysis also suggested that reductions
in joint cavity widening were greatest and PD
signals were lowest in patients with RA disease
duration of 1 year or less (Fig. 6c, d).
Safety
During the trial, 301 AEs occurred in 94 patients
(71.2%) and 25 of these AEs were considered
serious (Supplementary Table S3). The most
common TEAEs occurring during the study
were within the MedDRA SOC ‘‘infections and
infestations’’, which occurred in 49 patients
(37.1%), including influenza viral infections (15
patients, 11.4%), herpes viral infections (12
patients, 9.1%), and upper and lower respiratory
Fig. 3 Evaluation of a positive predictive values (PPV),
b area under the curve (AUC), and c negative predictive
values (NPV) of clinical response at time points up to week
12. Data are reported for the full analysis set (RA duration
of at most 1 year, n = 29; RA duration greater than 1 year,
n = 102). Missing data were imputed using non-responder
imputation (NRI). Data are provided for observed cases
(OC) and NRI. Clinical responses at week 1 to week 12
were deﬁned as a reduction of at least 1.2 from baseline in
DAS28(ESR). AUC and NPV data were unavailable for
patients with RA duration of at most 1 year (OC) at week
12. AUC area under the curve, NPV negative predictive
value, NRI non-responder imputation, OC observed case,
PPV positive predictive value, RA rheumatoid arthritis
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tract and lung infections (9 patients, 6.8%
each); reported by preferred term. Overall, three
patients (2.3%) reported a total of four serious
infections [abdominal and gastrointestinal, eye
and eyelid infections, lower respiratory tract
and lung infections, and salmonella infections,
each reported by one patient (0.8%)] and dis-
continued CZP treatment as a result. Infections
were considered severe in two patients (1.5%).
Malignant tumors were reported in three
patients (2.3%) and included one case (0.8%)
each of lobular breast carcinoma in situ, non-
Hodgkin’s lymphoma, and malignant mela-
noma in situ. No deaths were reported over the
course of the study (Supplementary Table S3).
DISCUSSION
In Italian CZP-treated RA patients, clinical
response up to week 12 may be predictive of
long-term response at week 52, independently
of the following prognostic factors within the
post hoc analysis: baseline DAS28(ESR)\ 5.1
and C 5.1, gender, age (\65 and C 65 years),
and duration of RA (B 1 and[1 year). How-
ever, the cutoff values used for these prognostic
factors may not have been sufficient to identify
changes; additionally, other baseline character-
istics that were not selected and tested might
have had an impact on predicting long-term
response to CZP. The DAS28(ESR) results
demonstrate that there was a ‘‘predictive win-
dow’’, between week 4 and week 12, which was
the most predictive of a long-term response to
treatment. Patients with RA disease duration of
1 year or less had numerically lower rates of
DAS28(ESR) response compared to patients with
more established disease. Similarly, patients
with disease duration of at least 1 year had
higher PPV outcomes compared to patients
with shorter disease duration. This does not
align with previous reports in which disease
duration was not a significant predictor of good
DAS28 response rates or ACR20 response rates
[33, 34]. The improvements in patient-reported
HAQ-DI and PtAAP from baseline to week 52
show that in addition to the observed
improvements in disease activity, patients
experienced a better health-related quality of
life, with less pain, over the duration of the
study. The proportion of patients in the FAS
completing the study to week 52 was 70%
Fig. 4 DAS28(ESR) response logistic regression analysis.
Data are reported for the full analysis set (n = 131). Data
were imputed using non-responder imputation (NRI).
[a]Early responders were deﬁned as the response, for each
patient, at the visit where the highest area under curve
(AUC) was observed. Clinical response at week 52 is
deﬁned as a reduction of at least 1.2 from baseline in
DAS28(ESR). The odds ratio, CI and p value are from a
logistic regression model with early responders as ﬁxed
effects and baseline DAS28(ESR) score, gender, age, and
duration of RA as factors. An odds ratio greater than 1
indicates a higher response rate in the ﬁrst category [e.g.,
DAS28(ESR) C 5.1] compared to the second category
[e.g., DAS28(ESR)\ 5.1]. CI conﬁdence interval, DAS28
28-joint disease activity score, ESR erythrocyte sedimen-
tation rate, RA rheumatoid arthritis
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which is in line with the retention rates
observed in the RAPID-1 and RAPID-2 ran-
domized clinical trials at week 52 and week 24,
respectively [35, 36]. Similar retention rates
have also been observed in patients randomized
to receive etanercept treatment after 2 years
[37], and the National Swedish registry which
assessed the effectiveness of CZP in patients
with RA [38].
CZP-treated patients also experienced a rapid
improvement in PDUS outcomes, which was
then sustained to 1 year. Ultrasound has been
shown to have a higher sensitivity and accuracy
in detecting inflammation and anatomical
damage resulting from RA than clinical and
radiographic examinations [39, 40]. Studies
have also indicated that PDUS is an effective
method of measuring the response of RA
symptoms to anti-TNF therapy [41, 42]. This
study used PDUS to assess the response of RA
patients to CZP treatment and a rapid decrease
was observed in joint cavity widening and PD
signal/blood flow from the start of CZP treat-
ment up to week 8, which then remained
stable throughout the remainder of the trial
period. Mean bone erosion and cartilage dam-
age, measured by PDUS, remained
stable throughout the duration of the study.
These findings were complemented by
stable mean mTSS radiographic measurements
to week 52, and PDUS and mTSS measurements
were not significantly correlated when com-
pared. Improvement in ultrasound outcomes
has been observed in studies investigating other
biologic agents, such as adalimumab, etaner-
cept, infliximab, and tocilizumab [43–48] as
well as in a recent case study using CZP in an RA
patient [49]. Ultrasound bone erosion has also
been described as a relapse risk factor in a recent
observational study after discontinuation of
Fig. 5 Improvements in clinical and patient-reported
outcomes up to week 52 of the CZP-SPEED study. Data
are reported for the full analysis set (n = 131). Missing
data were imputed using last observation carried forward
for continuous variables and non-responder imputation for
binary data. Patients rated their level of arthritis pain on a
100 mm VAS, where 0 indicated ‘‘no pain’’ and 100
indicated ‘‘most severe pain’’. DAS28 28-joint disease
activity score, ESR erythrocyte sedimentation rate, HAQ-
DI health assessment questionnaire disability index, LOCF
last observation carried forward, NRI non-responder
imputation, PtAAP patient assessment of arthritis pain,
VAS visual analogue scale (0–100 mm)
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biological therapies [50]. However, because of
the heterogeneity of study designs, the studies
cannot be directly compared.
RA duration was found to be a predictive
baseline characteristic to explain PDUS results
over time; post hoc analyses suggest that early
RA patients with a disease duration less than
1 year experienced greater reductions in grays-
cale and PD findings (indicative of inflamma-
tion) compared to those with disease duration
between 1 and 2 years. However, patient num-
bers in the subgroup comparisons were low.
In this study, cartilage damage and bone
erosion were not found to worsen after the start
of treatment and remained stable. This result
was consistent with our hypothesis and almost
all previous studies that demonstrated that anti-
TNF treatment alone could slow down the
decrease of bone mineral density [51] and car-
tilage damage, both as monotherapy [52], and
when used alongside concomitant DMARD
treatment [53]. No new safety signals were
identified during this study, comparative with
the current knowledge about CZP [54].
Limitations of this study included the open-
label, single-arm study design, which may have
introduced bias in favor of treatment response.
This study also had a small sample size com-
pared to the RAPID-1 trial [7]; however, our
observations support the finding that
DAS28(ESR) response rates at week 12 are pre-
dictive of disease activity at 52 weeks. Another
Fig. 6 Mean improvement in joint cavity widening (a,
c) and PD signal (b, d) measured with PDUS over time in
metacarpophalangeal joints (MCPs). Groups are analyzed
by MCP joint, n = 66 (a, b) and duration of RA (c, d).
Data are reported for the full analysis set in patients
eligible for the PDUS subgroup (n = 66). Joint cavity
widening scores (0–3 scale; 0 = no effusion/hypertrophy,
1 = minimal effusion/hypertrophy, 2 = moderate effu-
sion/hypertrophy, 3 = extensive effusion/hypertrophy).
Power Doppler signal was based on the 4-point scale
ranging from 0 (normal/minimal blood ﬂow) to 3 (marked
blood ﬂow). Missing values were imputed using last
observation carried forward (LOCF). Patients within the
PDUS subset had at most 2 years duration of RA and
proof of at least two of the following: synovial prolifer-
ation, synovial vascularization, or presence of ﬂuid in at
least one MCP joint. MCP metacarpophalangeal joints,
PD Power Doppler, PDUS Power Doppler ultrasound, RA
rheumatoid arthritis
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limitation was the potential variability in the
interpretation of PDUS images, since ultra-
sonographers were based at individual sites as a
result of the multicenter nature of the study.
However, this was mitigated by all ultrasonog-
raphers being experts who used appropriate
equipment and followed predefined recom-
mendations to align the definition of scanning
method and standardize scoring. Inter-reader
reliability was also quantified through the re-
assessment of all images by a second experi-
enced ultrasonographer and showed a decrease
in reliability over the course of the study. This
may be due to the observed decrease in disease
activity over time, as variability has been shown
to be at a maximum when image subscores are
between 1 and 2, where loss of sharpness, or a
partial thickness defect, is observed in the car-
tilage layer [29].
CONCLUSIONS
This study found that clinical response to week
12 in RA patients treated with CZP may be
predictive of response at week 52. A rapid
decrease in PDUS-measured joint cavity widen-
ing and PD signal was observed to week 8,
which was then maintained to week 52. In
addition, no progression in cartilage damage or
bone erosion was observed. No new safety sig-
nals were identified during this study, compar-
ative with the current knowledge about CZP
[54] and other anti-TNF therapies [55].
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Table 2 Mixed effect repeated measures analysis reporting the overall mean differences in the sum score for joint cavity
widening, synovial proliferation, and PD signal and cartilage damage, and bone erosions
Fixed effect Sum score for joint cavity widening,
synovial proliferation, and PD signal
Sum score for cartilage damage and
bone erosions
Mean
difference
95% CI p value Mean
difference
95% CI p value
DAS28(ESR) (C 5.1 vs\ 5.1) 1.01 - 1.61,
3.64
0.44 0.08 - 4.72,
4.89
0.97
Gender (female vs male) 2.27 - 0.45,
4.99
0.10 1.26 - 3.71,
6.24
0.61
Age (C 65 years vs\ 65 years) - 1.60 - 4.13,
0.93
0.21 0.67 - 3.95,
5.30
0.77
Duration of RA (C 1–\ 2 years vs
\ 1 year)
2.96 0.62, 5.30 0.01 5.31 1.03, 9.58 0.02
Data are reported for the full analysis set (FAS). Missing data were imputed using last observation carried forward (LOCF).
The regression coefﬁcients, 95% conﬁdence intervals and p values are from a mixed effects linear model for repeated
measures with baseline DAS28-ESR score, gender, age, and duration of RA as ﬁxed effects, and week as the repeated
measure. PDUS outcomes were analyzed by disease activity (sum score for joint cavity widening, synovial proliferation, and
PD signal) and disease severity (sum score for cartilage damage and bone erosions) post hoc. Differences show the overall
mean differences between the levels of the independent variables [i.e., DAS28(ESR) C 5.1 compared to DAS28(ESR)\
5.1]. Mean differences[ 0 indicate that the sum score for the ﬁrst category of the ﬁxed effect is greater than the second
category
CI conﬁdence interval, DAS disease activity score, ESR erythrocyte sedimentation rate, FAS full analysis set, LOCF last
observation carried forward, PD Power Doppler, PDUS Power Doppler ultrasound, RA rheumatoid arthritis, SE standard
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